Testing nipple discharge to tell benign from malignant breast disease
Part of Cancer, Skin, Women’s health & pregnancy clinical trials.
This study uses a blood test and a sample of nipple discharge to see if it can help doctors tell the difference between non-cancerous and cancerous conditions in the breast ducts. It aims to find a better way to diagnose intraductal disease without needing surgery right away.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have spontaneous, bloody or pinkish nipple discharge from one breast only.
- Your doctor has recommended surgery or a biopsy to check the breast ducts.
- You can provide a nipple discharge sample and one tube of blood before surgery.
- You are willing to sign a consent form and let researchers see your medical records.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new glowing needle that helps doctors find and sample tiny abnormal areas in breast ducts during surgery. It aims to make the procedure more precise.
This study looks for tiny bits of cancer DNA in your blood after breast cancer surgery. A blood test called NGS may help doctors find early signs of cancer coming back, and you would give samples and have checkups for 3 years.
This study looks at proteins and imaging patterns (from tissue, fluid near the tumor, and blood) to better understand breast cancer markers. It may help researchers find clues that doctors can use to evaluate breast nodules and newly diagnosed invasive breast cancer.
This study looks at tiny particles released by cells (called extracellular vesicles) in people with breast cancer. It may help researchers better understand breast cancer and how it behaves, which could improve future testing or treatments.
This trial tests a special needle that glows to help surgeons find and remove high-risk breast lesions. If you've already had a breast lesion found by ductoscopy and a duct excision, you might be able to join.
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.